Home > Insider Trading > Filing (0001209191-17-021366)

Filing Details

Accession Number:: 0001209191-17-021366
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-03-17 16:19:21
Reporting Period:: 2017-03-15

Filing Date:: 2017-03-17
Accepted Time:: 2017-03-17 16:19:21
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1539029	Clearside Biomedical Inc.	CLSD	Pharmaceutical Preparations (2834)	452437375

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1592380	Clay Thorp	C/O Clearside Biomedical, Inc. 1220 Old Alpharetta Road, Suite 300 Alpharetta GA 30005		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2017-03-15	47,000	$6.47	4,078,849	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2017-03-16	21,485	$6.77	4,057,364	No	4	S	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holders of the securities on September 16, 2016.
Consists of (i) 1,382 shares sold by Hatteras NC Fund, LP ("Hatteras NC"), (ii) 18,025 shares sold by Hatteras Venture Partners III, LP ("HVP III"), (iii) 1,636 shares sold by Hatteras Venture Affiliates III, LP ("HVA III"), (iv) 2,914 shares sold by Hatteras Venture Partners IV, LP ("HVP IV") and (v) 23,043 shares sold by Hatteras Venture Partners IV SBIC, LP ("HVP IV SBIC").
This transaction was executed in multiple trades at prices ranging from $6.10 to $6.77, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
The reporting person is one of the general partners of: (i) Hatteras Venture Advisors III, LLC, the general partner of HVP III and HVA III; (ii) Hatteras Venture Advisors IV SBIC, LLC, the general partner of HVP IV SBIC; and (iii) Hatteras Venture Advisors IV, LLC, the general partner of HVP IV and Hatteras NC. HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC are the record holders of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC.
The reporting person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.
Consists of (i) 631 shares sold by Hatteras NC, (ii) 8,239 shares sold by HVP III, (iii) 747 shares sold by HVA III, (iv) 1,332 shares sold by HVP IV and (v) 10,536 shares sold by HVP IV SBIC.
This transaction was executed in multiple trades at prices ranging from $6.46 to $6.94, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.